Edwards Lifesciences Impairment and restructuring decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $4.20M to $0.00. This increase may warrant attention — for this metric, lower values are generally preferred.
Lower is generally better as it indicates stability, though restructuring can be a positive signal of management proactively improving future efficiency.
This metric captures non-recurring charges related to the impairment of assets or organizational restructuring, such as...
Company-specific; peers may report these under 'Special Charges' or 'Other Operating Expenses'.
msft_impairment_and_restructuring| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.18M | $15.18M | $15.18M | $15.18M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.20M | $4.20M | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | — | — | — | +0.0% | -100.0% |
| YoY Change | — | — | — | — | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | -100.0% |